Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...

Dr. Anjana Pillai explains, in an interview with CURE, that treatment for liver cancer depends heavily on stage, liver ...

Liver cancer screening uses ultrasound and AFP biomarker tests, with CT or MRI for further evaluation if abnormalities are ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Merck and Eisai halt late-stage trial as Keytruda/Lenvima combo fails to improve survival in liver cancer. Read more here.

A Lisburn family is desperately bidding to give their mum her life back with lifesaving cancer treatment available in the USA ...

A Shropshire woman with a deadly cancer has been fundraising for life-extending treatment through bake sales. NHS worker ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at developing it as a partner drug to Keytruda. The combination has been approved for ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Eisai have announced that they will shut down the ...

A cancer patient who works at the NHS is trying to raise £120,000 for chemotherapy after she was refused the treatment. Jamie ...

As the incidence of obesity continues to rise nationally and globally, a new observational study published in Cancer reports ...